GlassScriptPhysician profile
Frances Robles-Pena
NPI 1033180633
$1,855.48
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,033 · 2020: $595 · 2021: $227.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $555.20 | 2019-2021 | |
| Abbvie INC. | $292.58 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $237.12 | 2019-2021 | |
| Gilead Sciences, INC. | $227.27 | 2019-2020 | |
| Allergan, INC. | $198.05 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $91.42 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.85 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $72.18 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $40.61 | 2020 | |
| Braintree Laboratories, INC. | $24.05 | 2019 | |
| Evoke Pharma, INC. | $21.94 | 2020 | |
| Redhill Biopharma INC. | $11.21 | 2020 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Robles-Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.